FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.

T. Rowe Price

venBio Partners

Blue Pool Capital

6 Dimensions Capital

Casdin Capital

Google Ventures

HBM Healthcare Investments AG

Invus

Deerfield

Farallon Capital Management

The Pags Group

ARCH Venture Partners

Cormorant Asset Management

Deerfield Management

Fidelity

Fidelity Management and Research Company

FogPharma

We gathered for our first annual winter party at the Boston Flight Club, a social darts venue. It was a great time of playing, mingling, and a little friendly competition. We take pride in our close-knit company culture and are excited to see our team members growing closer together as we pave a new way for transformative medicines as part of our collective moonshot mission. 

We're pleased to welcome Richa Poddar, MBS, to our team as Vice President, New Product Planning. Richa will play an integral role in achieving our ambitious goal to be a unique creator of life-changing medicines, by optimizing the competitive positioning of our portfolio of programs as they are developed for the market. Earlier in her career, she played an instrumental role in launching #oncology and rare disease products, and we look forward to having her on our team to help create transformative precision therapeutics for patients suffering from devastating and often fatal diseases such as #cancer.

February 4 is #WorldCancerDay, and we at FogPharma are taking a stand to #closethecaregap in cancer treatment. 

At a systemic level, we know that inequalities in healthcare access disproportionately affect many people. We are committed to providing equitable access to our clinical trials and potentially transformative precision medicines for often fatal and devastating diseases such as cancer. Our mission is to make these treatments available to everyone who needs them. We have designed our ongoing Phase 1/2 clinical trial of FOG-001 with #healthequity in mind by selecting a diverse group of clinical trial investigators at some of the nation’s most renowned cancer centers and enabling them to provide patients and their caregivers with translation services and travel reimbursement.

Read more about World Cancer Day, and join us in learning how you can help reduce inequities in #cancer care here: https://lnkd.in/drnuZeE

Image by World Cancer Day 

Join us in welcoming Mark Ator, Ph.D., to the Fog team as our Associate Vice President, Discovery DMPK! Mark brings over 35 years of #drugdiscovery and early drug development experience, with specialties in biochemistry, drug metabolism, and pharmacokinetics. He also has extensive experience as a discovery project team leader, advancing four projects into preclinical development. We're happy to have him on board as we continue to integrate the latest breakthroughs in experimental science and #datascience to create a new class of transformative medicines for patients. 

HSTS

DMARC

Person Schema

Google

Google Cloud

Gravatar Profiles

DigiCert SSL

Network Solutions DNS

Apple iCloud Mail

Scientific Co-Founder and Vice President, De Novo Discovery

John McGee

Chief Business Officer and Chief Financial Officer

Tony Gibney

Co-Founder and Chief Operating Officer

Weiqing Zhou

Vice President Exploratory Chemistry

Charles Johannes

Associate Vice President, Head of Computational Drug Discovery

Donovan Chin

Executive Vice President, Discovery Biology

Jonathan Hurov

Vice President, Medicinal Chemistry

Martin Tremblay

Vice President of Pharmaceutical Development

Theodore Martinot

Executive Vice President, Finance

Thomas Kotarakos

Senior Director Clinical Operations

Amanda Garofalo

Rick Klausner

Barbara Weber

Corey Goodman

Greg Verdine

Founder, CEO, CSO

Co-founder & COO

Stephen Fair

VP of Finance

Sandra Smith

Vice President and Head of People

Keith Orford

Chief Medical Officer & EVP of Clinical and Translational Science

Vice President of Chemistry

VP of Pharmaceutical Development

Fang Wang

Vice President of Biology

Northeastern US Late Stage Companies With More Than 10 Employees

Greater Boston Area Biotechnology Companies

Biopharma Companies

Biotechnology Late Stage Companies With Less Than $50M in Revenue

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.

It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.

Nextech Invest

Series E - FogPharma

Series D - FogPharma

Series C - FogPharma

Venture Round - FogPharma

Series B - FogPharma

Series A - FogPharma

Cambridge

Massachusetts

United States

North America

Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform

FogPharma rebrands as Parabilis Medicines, as CEO Mathai Mammen highlights next drugs

Fogpharma and Artbio collaborate to create new class of α-radioligand therapeutics for solid tumors

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle ...

FogPharma’s Collaboration with ARTBIO

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer

FogPharma pulls in $145M to support cancer drug research

FogPharma Raises $145M in Series E Financing, Targets Solid Tumors

FogPharma raises $145 million in rare Series E round

A new class of precision medicines that combine the targeting strength and specificity of antibodies with the broad tissue distribution and intracellular target engagement of small molecules.

A first-in-class TCF-blocking β-catenin inhibitor currently in Phase 1/2 clinical trial.

A therapeutic targeting β-catenin, currently in the discovery stage.

A therapeutic targeting ERG, currently in the discovery stage.

A therapeutic targeting ERG/DNA binding, currently in the discovery stage.

Therapies using Helicons for alpha radioligand treatment, currently in the hit identification stage.

Philippines

Asia

India

Bangladesh

HTML5

Google Tag Manager

Google Analytics

DigiCert

F5 NGINX

Google Compute Engine

Google Maps API

Wordpress

GoDaddy

Vimeo

Compass Therapeutics is a pharmaceutical company focused on developing antibody therapeutics for cancer and other diseases.

Compass Therapeutics

Artiva is a biotechnology company specializing in developing novel therapies for cancer treatment.

Artiva

TScan is a biotechnology company dedicated to developing T cell receptor therapies for cancer and other diseases.

TScan

Polaris Pharmaceuticals Inc is a company engaged in the development of innovative cancer therapeutics.

Polaris Pharmaceuticals Inc

Lycera Corp is a biopharmaceutical company focused on developing novel immunomodulatory therapies for treating cancer and autoimmune diseases.

Lycera Corp

FogPharma is a clinical-stage company pioneering a new class of drugs, Helicons, to address the limitations of today’s precision medicines and achieve universal druggability. Their mission is to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that block abnormal physiological processes in ways previously imagined but considered impossible.

Chief Medical Officer

Member Board Of Directors

Senior Vice President, Clinical Development

Clinical Development Lead, Immuno-Oncology and Combinations DPU

Director, Clinical Development, Oncology

Associate Director - Clinical Pharmacology and Experimental Medicine/Oncology

Assistant in Biology

Research Fellow

Medical Intern

Chief Medical Officer at FogPharma

Associate Director, Machine Learning

Associate Director, Machine Learning and Computational Biology

Principal Scientist, Machine Learning

Senior Machine Learning Engineer

Senior Principal Scientific Computing Engineer

Principal Scientific Computing Engineer

Senior Programming Specialist

Visiting Researcher

Cooperative Education Student

Research Assistant

IAS Summer Research Fellow - Research Assistant

Intern

Computational Biology | Machine Learning | Data Science

Varun Shivashankar

Associate Director, De Novo Discovery

Senior Scientist,  Display Screening Team Lead

Protein Engineering, Evolution, and Assay Develpment Scientist; Site ESH Coordinator

Protein Optimization and Evolution Scientist

Postdoctoral Fellow

NIH F32 Postdoctoral Fellow

Associate Director, De Novo Discovery at FogPharma

Olena Tokareva

Senior Administrative Business Partner

Administrative Business Partner

Executive Assistant

Special Assistant to the Founder, Chairwomen & CEO of Care.com

Front Office Manager

Executive Housekeeper

Assistant Director of Housekeeping

Housekeeping Manager

Front Desk

PBX/Front Desk

VIP Check-In Receptionist

Ashley Kancler

Chief People Officer

Vice President, Global Talent Management

Vice President, Global Talent Management and Pharmaceutical Development HR

Senior Director, Human Resources

Director, People and Organization Effectiveness

Director, Leadership Development

Chief People Officer at FogPharma

Kristen Stants

Associate Director

Associate Director, Clinical Bioinformatics

Senior Scientist, Computational Biology (Tesaro)

Scientist II

Associate Research Scientist

Postdoctoral Research Scientist

Postdoctoral Associate

Associate Director at FogPharma

Xinwei Han

Senior Director, Biometrics

Biostatisticial Consultant

Senior Director, Head of Biometrics

Lead Biostatistician

Senior Director, Biometrics at Fog Pharma

Lalith Akella

CEO, President and Chairman

Executive Advisor

Board Member

Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Senior Vice President, Cardiovascular diseases, Metabolic diseases, Immunology and Oncology

Senior Vice President, R&D

Chairman and CEO, FogPharma & Former Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

news impact assignment basic	general	Mar 1, 2024 10:56 PM	be270ed1
public peers	general
news daily refresh	general	Jul 25, 2024 12:00 PM	69018f7e
news processing daily refresh	general	Jun 3, 2024 7:41 AM	57c9e291
news impact assignment daily	general	Jun 3, 2024 7:44 AM	fe4ec720
news processing basic	general	Mar 1, 2024 10:56 PM	0e13f31f
company summary	general	Jun 3, 2024 7:46 AM	5487e003
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	0fc8cbfc
crunchbase profile	general	Nov 25, 2024 11:35 AM	0e1d51ab
li profile	general	Mar 1, 2024 10:56 PM	157cfce0
translate crunchbase fundingrounds	general	Nov 25, 2024 2:17 PM	57b681f4
peers	general
news basic	general	Mar 1, 2024 10:56 PM	82460319
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FOGPHARMA

FogPharma